Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmarise HoldingsTSE:2796 -0.61%50 Median PS Value is 円694.38 as of Jul. 21, 2026, which is 100% below its 10-year median of 1.05. GuruFocus rates TSE:2796 with a GF Score™ of 50/100 and a GF Value™ of 円608.01 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 262 Healthcare Providers & Services companies, Pharmarise Holdings ranks better than 50% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Pharmarise Holdings's Median PS Value or its related term are showing as below:
TSE:2796'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.71 Med: 1.05 Max: 1.13
Current: 0.71
During the past 13 years, the highest Price to Median PS Value of Pharmarise Holdings was 1.13. The lowest was 0.71. And the median was 1.05.
TSE:2796's Price-to-Median-PS-Value is ranked better than 50% of 262
companies
in the Healthcare Providers & Services industry
Industry Median: 0.71
vs TSE:2796: 0.71
Pharmarise Holdings (TSE:2796) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Pharmarise Holdings's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
491.00
/
694.38
=
0.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmarise Holdings Median PS Value Related Terms
Pharmarise Holdings Median PS Value Historical Data
* Premium members only.
The historical data trend for Pharmarise Holdings's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmarise Holdings Median PS Value Competitor Comparison
For the Pharmaceutical Retailers subindustry, Pharmarise Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmarise Holdings Price-to-Median-PS-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharmarise Holdings's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Pharmarise Holdings's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.1156.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pharmarise Holdings's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 was 円6008.27.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmarise Holdings (TSE:2796) has a Median PS Value of 円694.38 as of Jul. 21, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Pharmarise Holdings and its competitors. This is 66031% above median its historical median of 1.05. Over the past decade, Pharmarise Holdings' Median PS Value has ranged from 0.71 to 1.13. According to the industry distribution chart, Pharmarise Holdings ranks #131 out of 262 companies in the Healthcare Providers & Services industry, placing it in the top 50%.
Is Pharmarise Holdings' Median PS Value too high?
Pharmarise Holdings' current Median PS Value of 円694.38 is 66031% above median its 10-year median of 1.05. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 1.13. Based on the distribution chart, Pharmarise Holdings ranks #131 out of 262 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Pharmarise Holdings has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmarise Holdings' Median PS Value compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Pharmarise Holdings ranks #131 out of 262 companies for Median PS Value. This puts Pharmarise Holdings in the upper half of its industry. The industry median Median PS Value is 0.71. Historically, Pharmarise Holdings' own Median PS Value has ranged from 0.71 to 1.13 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Healthcare Providers & Services company?
The median Median PS Value among Healthcare Providers & Services companies is 0.71, based on 262 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Pharmarise Holdings and its competitors. For the Healthcare Providers & Services industry, the median Median PS Value is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmarise Holdings's current Median PS Value is 円694.38, which is 66031% above median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmarise Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmarise Holdings (TSE:2796) is currently considered Modestly Undervalued. The stock's GF Value™ is 円608.01, compared to a current price of 円491.00 — trading 19.2% below its estimated fair value. The current Median PS Value is 円694.38, which is 66031% above median its 10-year median of 1.05. Pharmarise Holdings' overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Pharmarise Holdings (TSE:2796), the current Median PS Value is 円694.38 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmarise Holdings (TSE:2796) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmarise Holdings stock appears to be undervalued.
The current stock price of 円491.00 is trading 19.2% below its estimated GF Value™ of 円608.01.
GuruFocus considers Pharmarise Holdings to be Modestly Undervalued.
Key valuation signals for TSE:2796:
Median PS Value: 円694.38 (66031% above median its 10-year median of 1.05)
GF Value™: 円608.01 vs. price of 円491.00 (19.2% below fair value)
No single metric tells the full story. See the TSE:2796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmarise Holdings Corp is engaged in the operation of dispensing pharmacies, which prescribe medicines to general patients based on the prescriptions issued by medical institutions. It is also engaged in the storage and management of medical examination records of patients on behalf of the medical institution.
50GF Score
Get the complete analysis for TSE:2796
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2796 has been successfully added to your 
